Peptide Recovery Stacks: BPC-157 + TB-500 + GHK-Cu Protocols

Single peptides address single mechanisms. Stacking addresses injuries from multiple angles simultaneously — angiogenesis, inflammation, collagen synthesis, and immune modulation working in parallel rather than sequence. The three most commonly stacked recovery peptides — BPC-157, TB-500, and GHK-Cu — each hit different repair pathways, and the combination has become the standard protocol in the biohacking recovery space.

This guide covers the evidence behind multi-peptide stacking, specific protocols for different injury types, dosing timelines, and the practical logistics of running a recovery stack.

The Three Mechanisms

BPC-157: The Tissue Healer

BPC-157 upregulates VEGF (vascular endothelial growth factor), promoting new blood vessel formation at the injury site. It also modulates the nitric oxide system, stabilizes growth factor pathways (EGF, FGF), and has demonstrated gut-protective effects across dozens of animal models. In practical terms: BPC-157 accelerates the vascular supply that delivers healing resources to damaged tissue.

TB-500: The Mobility Restorer

TB-500 (Thymosin Beta-4 fragment) works through a different mechanism — it promotes actin polymerization (cellular scaffolding formation), reduces inflammation through IL-6 modulation, and facilitates cell migration to the injury site. Where BPC-157 builds the supply lines, TB-500 mobilizes the repair crews. Users frequently report improved range of motion and reduced stiffness before measurable structural healing occurs.

GHK-Cu: The Remodeler

GHK-Cu activates tissue remodeling at the gene expression level. It stimulates collagen synthesis (Types I and III), activates metalloproteinase pathways for scar tissue remodeling, and modulates over 4,000 genes toward patterns associated with younger, healthier tissue. Adding GHK-Cu to a recovery stack addresses the remodeling phase — the point where new tissue forms but needs to be organized into functional structure.

The Wolverine Stack: BPC-157 + TB-500

Loading vs. Maintenance Phasing

TB-500 protocols typically use a loading phase (higher dose, more frequent) followed by a maintenance phase:

Weeks 1–2 (Loading): TB-500 2–2.5 mg twice per week + BPC-157 500 mcg daily near the injury site.

Weeks 3–6 (Maintenance): TB-500 2 mg once per week + BPC-157 250–500 mcg daily.

The loading phase front-loads the anti-inflammatory and cell-migration effects. Maintenance sustains the healing environment while BPC-157 continues promoting angiogenesis.

The Full Recovery Stack: BPC-157 + TB-500 + GHK-Cu

Adding GHK-Cu to the Wolverine Stack creates a three-phase recovery approach:

Phase 1 (Acute — Week 1–2): BPC-157 500 mcg/day + TB-500 2.5 mg 2x/week. Focus on reducing inflammation and initiating repair.

Phase 2 (Repair — Week 3–4): Continue BPC-157 500 mcg/day + TB-500 2 mg/week. Add GHK-Cu 200–500 mcg/day (SubQ) or topical application over the injury site. Focus shifts to tissue formation and remodeling.

Phase 3 (Remodeling — Week 5–8): BPC-157 250 mcg/day (taper) + GHK-Cu 200 mcg/day. TB-500 may be discontinued. Focus on collagen organization and functional tissue maturation.

Injury-Specific Protocols

Practical Logistics

Timing: BPC-157 is typically administered once or twice daily. TB-500 is administered 2x/week during loading, 1x/week during maintenance. GHK-Cu can be administered daily. Some protocols time BPC-157 injections in the morning and evening to maintain more consistent tissue levels.

Injection sites: BPC-157 should be injected subcutaneously near the injury when possible (within a few inches). TB-500 can be injected anywhere subcutaneously — it distributes systemically regardless of injection site. GHK-Cu can be injected near the target tissue or applied topically if the target is skin.

Can you mix in the same syringe? BPC-157 and TB-500 can be combined in the same injection to reduce needle sticks. GHK-Cu should generally be administered separately due to the copper ion's potential to interact with other peptides in solution.

Where to Source Recovery Peptides

Frequently Asked Questions

Related Articles